Baker McKenzie advised CureVac, a global biopharmaceutical company developing transformative medicines based on messenger ribonucleic acid (mRNA), on restructuring its existing collaboration with GSK into a new licensing agreement, allowing each company to prioritize investment
Tags :dx2
Bregal Unternehmerkapital, advised by Walder Wyss, entered into an agreement to acquire a majority stake in BSI Software, a provider of Customer Relationship Management (CRM) and Customer Experience (CX) software solutions advised by Niederer Kraft
Homburger advised International Business Machines Corporation (“IBM”) on its definitive agreement with Software AG, advised by Niederer Kraft Frey (“NKF”) and owned by Silver Lake, to purchase StreamSets and webMethods, Software AG’s Super iPaaS (
Lenz & Staehelin advised Navegar on its additional follow-on investment in Swiss-based Dali Discount, a hard discounter in Southeast Asia. Navegar is a Manila-based private equity firm that provides growth capital to established companies. Lenz &
Niederer Kraft Frey (“NKF”) promotes Lukas Fahrländer (pictured) to senior associate, effective 1 July 2024. Lukas Fahrländer Lukas Fahrländer is a member of the banking, finance & regulatory team. He advises Swiss and international
Advestra advised Liberta Partners on the acquisition of the Swiss e‑commerce company DeinDeal from Ringier, which held a majority stake in DeinDeal since 2015. Advestra’s
Homburger advised Meyer Burger Technology on the completion of a reverse split (on July 1, 2024) of its shares in the ratio 750:1, which had been approved by its annual general meeting of shareholders held on June 25, 2024. The
Baker McKenzie Switzerland has appointed Dr. Valentina Hirsiger (pictured) as a new partner as of 1 July 2024. In her new role, Hirsiger will strengthen Baker McKenzie’s competence in the areas of Dispute Resolution, International Arbitration,
Bär & Karrer advised investor Coatue in an oversubscribed USD 10.7 million seed financing round for DeepJudge, advised by Wenger Vieli. The round also saw participation from several angel investors such as Gokul Rajaram and
Advestra advised Novartis on the issuance of CHF 2.2 billion bonds, placed in five tranches as follows: UBS, BNP Paribas (Suisse) and Deutsche Bank Aktiengesellschaft acted as joint lead managers
